 Robert Breeze
Concepts (294)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fetal Tissue Transplantation | 15 | 2004 | 33 | 0.990 |
Why?
| | Parkinson Disease | 20 | 2011 | 600 | 0.980 |
Why?
| | Endolymphatic Hydrops | 2 | 2013 | 4 | 0.810 |
Why?
| | Meniere Disease | 2 | 2013 | 36 | 0.770 |
Why?
| | Trigeminal Neuralgia | 2 | 2019 | 15 | 0.640 |
Why?
| | Surgical Instruments | 3 | 2019 | 51 | 0.630 |
Why?
| | Microvascular Decompression Surgery | 1 | 2019 | 4 | 0.600 |
Why?
| | Polytetrafluoroethylene | 1 | 2019 | 25 | 0.590 |
Why?
| | Intracranial Aneurysm | 5 | 2018 | 102 | 0.470 |
Why?
| | Brain Tissue Transplantation | 8 | 2004 | 19 | 0.450 |
Why?
| | Cell Transplantation | 2 | 2011 | 39 | 0.430 |
Why?
| | Ear, Inner | 1 | 2013 | 51 | 0.390 |
Why?
| | Dopamine | 8 | 2009 | 283 | 0.350 |
Why?
| | Meningioma | 2 | 2009 | 86 | 0.330 |
Why?
| | Dopaminergic Neurons | 1 | 2011 | 67 | 0.330 |
Why?
| | Reperfusion Injury | 1 | 2013 | 300 | 0.330 |
Why?
| | Osteochondroma | 1 | 2009 | 10 | 0.310 |
Why?
| | Meningeal Neoplasms | 2 | 2009 | 93 | 0.310 |
Why?
| | Dura Mater | 1 | 2009 | 35 | 0.300 |
Why?
| | Clinical Trials as Topic | 3 | 2011 | 1050 | 0.260 |
Why?
| | Bone Neoplasms | 1 | 2009 | 253 | 0.260 |
Why?
| | Mesencephalon | 6 | 2003 | 64 | 0.240 |
Why?
| | Models, Biological | 1 | 2013 | 1820 | 0.230 |
Why?
| | Hemangioma, Cavernous | 2 | 2003 | 13 | 0.230 |
Why?
| | Radiosurgery | 3 | 2018 | 400 | 0.220 |
Why?
| | Brain Neoplasms | 5 | 2018 | 1318 | 0.210 |
Why?
| | Craniotomy | 4 | 2019 | 82 | 0.190 |
Why?
| | Mutism | 1 | 2002 | 7 | 0.180 |
Why?
| | Dihydroxyphenylalanine | 4 | 2009 | 9 | 0.180 |
Why?
| | Central Nervous System Neoplasms | 1 | 2003 | 173 | 0.170 |
Why?
| | Brain Stem Neoplasms | 1 | 2002 | 87 | 0.170 |
Why?
| | Cerebral Hemorrhage | 1 | 2002 | 120 | 0.170 |
Why?
| | Subarachnoid Hemorrhage | 2 | 2018 | 70 | 0.170 |
Why?
| | Nerve Fibers | 1 | 2001 | 104 | 0.170 |
Why?
| | Neurons | 4 | 2003 | 1640 | 0.160 |
Why?
| | Humans | 51 | 2019 | 144261 | 0.140 |
Why?
| | Tomography, Emission-Computed | 7 | 2003 | 71 | 0.140 |
Why?
| | Loeys-Dietz Syndrome | 1 | 2018 | 6 | 0.140 |
Why?
| | Carotid Artery Injuries | 1 | 1998 | 39 | 0.130 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 104 | 0.130 |
Why?
| | Aneurysm, Ruptured | 1 | 2018 | 37 | 0.130 |
Why?
| | Choroid Plexus Neoplasms | 1 | 1997 | 8 | 0.130 |
Why?
| | Papilloma | 1 | 1997 | 49 | 0.130 |
Why?
| | Brain | 8 | 2009 | 2930 | 0.120 |
Why?
| | Adult | 25 | 2017 | 40262 | 0.120 |
Why?
| | Substantia Nigra | 3 | 2004 | 63 | 0.120 |
Why?
| | Middle Aged | 28 | 2017 | 35762 | 0.120 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 2009 | 53 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 264 | 0.120 |
Why?
| | Antibodies | 1 | 2018 | 401 | 0.120 |
Why?
| | Antiparkinson Agents | 5 | 2003 | 41 | 0.120 |
Why?
| | Parietal Bone | 1 | 1995 | 9 | 0.120 |
Why?
| | Quadriplegia | 1 | 1995 | 14 | 0.120 |
Why?
| | Bone Cysts | 1 | 1995 | 11 | 0.120 |
Why?
| | Rhabdomyolysis | 1 | 1995 | 23 | 0.120 |
Why?
| | Epidermal Cyst | 1 | 1995 | 12 | 0.110 |
Why?
| | Aged | 18 | 2018 | 25850 | 0.110 |
Why?
| | Head Injuries, Closed | 1 | 1995 | 49 | 0.110 |
Why?
| | Age Factors | 5 | 2013 | 3313 | 0.110 |
Why?
| | Levodopa | 3 | 2004 | 41 | 0.110 |
Why?
| | Fibromuscular Dysplasia | 1 | 2014 | 8 | 0.110 |
Why?
| | Magnetic Resonance Imaging | 10 | 2009 | 3857 | 0.110 |
Why?
| | Ehlers-Danlos Syndrome | 1 | 2014 | 16 | 0.110 |
Why?
| | Wounds, Nonpenetrating | 1 | 1998 | 316 | 0.110 |
Why?
| | Double-Blind Method | 9 | 2009 | 2025 | 0.110 |
Why?
| | Brain Diseases | 1 | 1995 | 152 | 0.100 |
Why?
| | Neurofibromatosis 1 | 1 | 2014 | 54 | 0.100 |
Why?
| | Cerebral Arteries | 1 | 2014 | 58 | 0.100 |
Why?
| | Male | 30 | 2018 | 72035 | 0.100 |
Why?
| | Collagen | 1 | 1996 | 455 | 0.100 |
Why?
| | Lymphoma | 2 | 2003 | 232 | 0.100 |
Why?
| | Melanoma | 2 | 2018 | 760 | 0.100 |
Why?
| | Audiometry, Evoked Response | 1 | 2013 | 15 | 0.100 |
Why?
| | False Negative Reactions | 1 | 2013 | 60 | 0.100 |
Why?
| | Autopsy | 1 | 2013 | 94 | 0.100 |
Why?
| | Alleles | 1 | 1996 | 878 | 0.100 |
Why?
| | Aged, 80 and over | 2 | 2018 | 8243 | 0.100 |
Why?
| | Temporal Bone | 1 | 2013 | 45 | 0.100 |
Why?
| | Pineal Gland | 2 | 1997 | 15 | 0.100 |
Why?
| | Cerebral Ventricles | 2 | 1991 | 54 | 0.090 |
Why?
| | Pressure | 1 | 2013 | 225 | 0.090 |
Why?
| | Female | 25 | 2018 | 77976 | 0.090 |
Why?
| | Chickenpox | 1 | 2013 | 81 | 0.090 |
Why?
| | Dyskinesias | 2 | 2002 | 20 | 0.090 |
Why?
| | Treatment Outcome | 10 | 2018 | 11643 | 0.090 |
Why?
| | Spinal Cord Injuries | 1 | 1995 | 240 | 0.090 |
Why?
| | Data Interpretation, Statistical | 1 | 2013 | 371 | 0.090 |
Why?
| | Pseudotumor Cerebri | 1 | 1991 | 32 | 0.090 |
Why?
| | Terminology as Topic | 1 | 2013 | 255 | 0.080 |
Why?
| | Intracranial Pressure | 1 | 1991 | 65 | 0.080 |
Why?
| | Follow-Up Studies | 8 | 2009 | 5389 | 0.080 |
Why?
| | Nerve Tissue | 1 | 1990 | 7 | 0.080 |
Why?
| | Skull Neoplasms | 2 | 2003 | 21 | 0.080 |
Why?
| | Embryonic Stem Cells | 1 | 2011 | 130 | 0.080 |
Why?
| | Hydrocephalus | 1 | 1991 | 111 | 0.080 |
Why?
| | Spinal Cord Diseases | 1 | 1990 | 41 | 0.080 |
Why?
| | Postoperative Complications | 2 | 2002 | 2916 | 0.080 |
Why?
| | Cysts | 1 | 1990 | 111 | 0.080 |
Why?
| | Herpes Zoster | 1 | 2013 | 315 | 0.080 |
Why?
| | Radiopharmaceuticals | 1 | 2009 | 194 | 0.070 |
Why?
| | Statistics as Topic | 1 | 2009 | 281 | 0.070 |
Why?
| | Cerebrospinal Fluid | 1 | 1989 | 88 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 1180 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 186 | 0.070 |
Why?
| | Point Mutation | 1 | 2009 | 243 | 0.070 |
Why?
| | Microtubule-Associated Proteins | 1 | 2009 | 196 | 0.070 |
Why?
| | Iridium | 1 | 1987 | 7 | 0.070 |
Why?
| | Pinealoma | 1 | 1987 | 9 | 0.070 |
Why?
| | Radioisotopes | 1 | 1987 | 33 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 1995 | 862 | 0.070 |
Why?
| | Encephalitis | 1 | 1989 | 139 | 0.060 |
Why?
| | Fetus | 2 | 1990 | 803 | 0.060 |
Why?
| | Brachytherapy | 1 | 1987 | 134 | 0.060 |
Why?
| | Proto-Oncogene Proteins | 1 | 2009 | 623 | 0.060 |
Why?
| | Magnetic Resonance Angiography | 2 | 2018 | 251 | 0.060 |
Why?
| | Disease Progression | 3 | 2018 | 2840 | 0.060 |
Why?
| | Adolescent | 7 | 2014 | 22281 | 0.050 |
Why?
| | Risk Factors | 2 | 2013 | 10699 | 0.050 |
Why?
| | Dopamine Agents | 1 | 2004 | 22 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2637 | 0.050 |
Why?
| | Transplantation | 1 | 2004 | 33 | 0.050 |
Why?
| | Putamen | 6 | 2003 | 22 | 0.050 |
Why?
| | Incidence | 2 | 2003 | 2870 | 0.050 |
Why?
| | Glioblastoma | 2 | 2003 | 353 | 0.050 |
Why?
| | Transplants | 1 | 2003 | 39 | 0.050 |
Why?
| | Cerebral Angiography | 3 | 1998 | 119 | 0.050 |
Why?
| | Young Adult | 3 | 2017 | 13990 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2009 | 2111 | 0.050 |
Why?
| | Granuloma, Foreign-Body | 1 | 2003 | 8 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2009 | 869 | 0.050 |
Why?
| | Transplantation, Heterologous | 1 | 2003 | 193 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2003 | 232 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2009 | 1165 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2003 | 322 | 0.050 |
Why?
| | Glioma | 1 | 1987 | 425 | 0.050 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1264 | 0.050 |
Why?
| | Parkinsonian Disorders | 1 | 2002 | 43 | 0.050 |
Why?
| | Reaction Time | 1 | 2004 | 438 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2003 | 191 | 0.050 |
Why?
| | Dysarthria | 1 | 2002 | 10 | 0.050 |
Why?
| | Cerebellar Nuclei | 1 | 2002 | 9 | 0.050 |
Why?
| | Confidence Intervals | 1 | 2002 | 333 | 0.040 |
Why?
| | Laminectomy | 2 | 1999 | 31 | 0.040 |
Why?
| | Preoperative Care | 1 | 2004 | 379 | 0.040 |
Why?
| | Globus Pallidus | 1 | 2001 | 25 | 0.040 |
Why?
| | Control Groups | 1 | 2001 | 12 | 0.040 |
Why?
| | Electric Stimulation Therapy | 1 | 2001 | 62 | 0.040 |
Why?
| | Cholesterol | 1 | 2003 | 399 | 0.040 |
Why?
| | Child, Preschool | 2 | 2013 | 11774 | 0.040 |
Why?
| | Thalamus | 1 | 2002 | 125 | 0.040 |
Why?
| | Movement | 3 | 2009 | 293 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2003 | 627 | 0.040 |
Why?
| | Neural Pathways | 1 | 2002 | 311 | 0.040 |
Why?
| | Stereotaxic Techniques | 3 | 1995 | 42 | 0.040 |
Why?
| | Placebos | 1 | 2000 | 192 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2009 | 780 | 0.040 |
Why?
| | Spinal Stenosis | 1 | 1999 | 31 | 0.040 |
Why?
| | Immunohistochemistry | 1 | 2003 | 1715 | 0.040 |
Why?
| | Motor Activity | 1 | 2004 | 720 | 0.040 |
Why?
| | Intervertebral Disc Displacement | 1 | 1999 | 41 | 0.040 |
Why?
| | Child | 4 | 2018 | 22537 | 0.040 |
Why?
| | Smooth Muscle Tumor | 1 | 1998 | 6 | 0.030 |
Why?
| | Genotype | 2 | 2009 | 1833 | 0.030 |
Why?
| | Sarcoma, Synovial | 1 | 1998 | 20 | 0.030 |
Why?
| | Dobutamine | 1 | 1998 | 24 | 0.030 |
Why?
| | Leiomyosarcoma | 1 | 1998 | 28 | 0.030 |
Why?
| | Aortography | 1 | 1998 | 52 | 0.030 |
Why?
| | Ligation | 1 | 2018 | 92 | 0.030 |
Why?
| | Gene Expression | 1 | 2003 | 1487 | 0.030 |
Why?
| | Prospective Studies | 2 | 2002 | 7970 | 0.030 |
Why?
| | Blood Volume | 1 | 1998 | 65 | 0.030 |
Why?
| | Leiomyoma | 1 | 1998 | 59 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 1999 | 252 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 1998 | 91 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2018 | 427 | 0.030 |
Why?
| | Inclusion Bodies | 1 | 1997 | 27 | 0.030 |
Why?
| | Cell Nucleolus | 1 | 1997 | 20 | 0.030 |
Why?
| | Drainage | 1 | 2018 | 185 | 0.030 |
Why?
| | Blotting, Southern | 1 | 1996 | 85 | 0.030 |
Why?
| | DNA Probes | 1 | 1996 | 59 | 0.030 |
Why?
| | Carotid Arteries | 1 | 1998 | 199 | 0.030 |
Why?
| | Animals | 5 | 2011 | 38030 | 0.030 |
Why?
| | Cytoplasm | 1 | 1997 | 269 | 0.030 |
Why?
| | Postoperative Care | 1 | 2018 | 288 | 0.030 |
Why?
| | Caudate Nucleus | 4 | 2002 | 21 | 0.030 |
Why?
| | Immobilization | 1 | 1995 | 53 | 0.030 |
Why?
| | Micromanipulation | 1 | 1995 | 14 | 0.030 |
Why?
| | Prevalence | 1 | 2002 | 2815 | 0.030 |
Why?
| | Aorta, Thoracic | 1 | 1998 | 286 | 0.030 |
Why?
| | Brain Edema | 1 | 1995 | 62 | 0.030 |
Why?
| | Cerebrovascular Circulation | 1 | 1998 | 278 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 688 | 0.030 |
Why?
| | Vision Disorders | 1 | 1997 | 178 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 3 | 1995 | 2730 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2018 | 17009 | 0.030 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 1995 | 177 | 0.030 |
Why?
| | Brain Ischemia | 1 | 1998 | 358 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2001 | 2917 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 1995 | 155 | 0.030 |
Why?
| | Visual Acuity | 1 | 1997 | 486 | 0.030 |
Why?
| | Equipment Design | 1 | 1995 | 530 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2000 | 1705 | 0.020 |
Why?
| | Brain Stem | 2 | 1992 | 95 | 0.020 |
Why?
| | Receptors, Dopamine | 1 | 1993 | 19 | 0.020 |
Why?
| | Radiography | 1 | 1995 | 842 | 0.020 |
Why?
| | Nerve Regeneration | 1 | 1993 | 56 | 0.020 |
Why?
| | Fluorine Radioisotopes | 2 | 2002 | 13 | 0.020 |
Why?
| | Body Water | 1 | 1991 | 23 | 0.020 |
Why?
| | Neurologic Examination | 4 | 1993 | 130 | 0.020 |
Why?
| | Acute Disease | 2 | 1998 | 1028 | 0.020 |
Why?
| | Emergency Medical Services | 1 | 1998 | 696 | 0.020 |
Why?
| | Syndrome | 1 | 1991 | 380 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2926 | 0.020 |
Why?
| | Adrenal Glands | 1 | 1990 | 77 | 0.020 |
Why?
| | Neostriatum | 1 | 2009 | 37 | 0.020 |
Why?
| | KRIT1 Protein | 1 | 2009 | 4 | 0.020 |
Why?
| | Corpus Striatum | 1 | 1990 | 179 | 0.020 |
Why?
| | Escherichia coli Infections | 1 | 1989 | 129 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2009 | 405 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 1988 | 163 | 0.020 |
Why?
| | Gene Frequency | 1 | 2009 | 481 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2009 | 323 | 0.020 |
Why?
| | Rabbits | 1 | 1989 | 648 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1992 | 2026 | 0.020 |
Why?
| | Time Factors | 4 | 1999 | 7155 | 0.020 |
Why?
| | Pituitary Neoplasms | 1 | 1988 | 190 | 0.020 |
Why?
| | Quality of Life | 1 | 1998 | 3166 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 2096 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 1988 | 748 | 0.010 |
Why?
| | Trigeminal Nerve | 1 | 1982 | 27 | 0.010 |
Why?
| | Corpus Callosum | 1 | 2003 | 72 | 0.010 |
Why?
| | Temporal Arteries | 1 | 2003 | 43 | 0.010 |
Why?
| | Temporal Lobe | 1 | 2003 | 104 | 0.010 |
Why?
| | Treatment Failure | 1 | 2003 | 363 | 0.010 |
Why?
| | Rats | 1 | 1990 | 5592 | 0.010 |
Why?
| | Frontal Lobe | 1 | 2003 | 159 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2004 | 328 | 0.010 |
Why?
| | Culture Techniques | 1 | 2001 | 67 | 0.010 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2003 | 758 | 0.010 |
Why?
| | Walking | 2 | 1999 | 545 | 0.010 |
Why?
| | Down-Regulation | 1 | 2003 | 627 | 0.010 |
Why?
| | Work | 1 | 1999 | 23 | 0.010 |
Why?
| | Up-Regulation | 1 | 2003 | 851 | 0.010 |
Why?
| | Reoperation | 1 | 1982 | 629 | 0.010 |
Why?
| | Lumbosacral Region | 1 | 1999 | 59 | 0.010 |
Why?
| | Ethics, Medical | 1 | 2000 | 86 | 0.010 |
Why?
| | Vascular Surgical Procedures | 1 | 1982 | 339 | 0.010 |
Why?
| | Recurrence | 1 | 1982 | 1134 | 0.010 |
Why?
| | Stem Cells | 1 | 2003 | 625 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2003 | 1129 | 0.010 |
Why?
| | Sella Turcica | 1 | 1998 | 17 | 0.010 |
Why?
| | Low Back Pain | 1 | 1999 | 106 | 0.010 |
Why?
| | Tumor Virus Infections | 1 | 1998 | 49 | 0.010 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 1998 | 65 | 0.010 |
Why?
| | Risk | 1 | 2000 | 909 | 0.010 |
Why?
| | Fatal Outcome | 1 | 1998 | 307 | 0.010 |
Why?
| | Biomarkers | 1 | 1988 | 4254 | 0.010 |
Why?
| | Pain | 1 | 1982 | 777 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 1998 | 176 | 0.010 |
Why?
| | Herpesviridae Infections | 1 | 1998 | 150 | 0.010 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 231 | 0.010 |
Why?
| | Spinal Fusion | 1 | 1999 | 260 | 0.010 |
Why?
| | Arteries | 1 | 1997 | 258 | 0.010 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 1995 | 21 | 0.010 |
Why?
| | Muscle Contraction | 1 | 1998 | 428 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2003 | 2829 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1995 | 223 | 0.010 |
Why?
| | Vasodilation | 1 | 1998 | 522 | 0.010 |
Why?
| | Primates | 1 | 1995 | 131 | 0.010 |
Why?
| | RNA, Viral | 1 | 1998 | 687 | 0.010 |
Why?
| | Prednisone | 1 | 1995 | 221 | 0.010 |
Why?
| | Cyclosporine | 1 | 1995 | 265 | 0.010 |
Why?
| | Transplantation, Homologous | 1 | 1995 | 415 | 0.010 |
Why?
| | Antibody Formation | 1 | 1995 | 294 | 0.010 |
Why?
| | Length of Stay | 1 | 1999 | 1335 | 0.010 |
Why?
| | Immunity, Cellular | 1 | 1995 | 272 | 0.010 |
Why?
| | Tissue Survival | 1 | 1992 | 16 | 0.010 |
Why?
| | Dominance, Cerebral | 1 | 1993 | 56 | 0.010 |
Why?
| | Spleen | 1 | 1995 | 508 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 1983 | 0.010 |
Why?
| | Lymph Nodes | 1 | 1995 | 502 | 0.010 |
Why?
| | Cohort Studies | 1 | 2002 | 5935 | 0.010 |
Why?
| | Video Recording | 1 | 1992 | 211 | 0.010 |
Why?
| | Spinal Cord | 1 | 1992 | 380 | 0.000 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 166 | 0.000 |
Why?
| | Cell Line | 1 | 1995 | 2879 | 0.000 |
Why?
| | Activities of Daily Living | 1 | 1992 | 440 | 0.000 |
Why?
| | Antigens, Nuclear | 1 | 1988 | 16 | 0.000 |
Why?
| | Motor Skills | 1 | 1990 | 104 | 0.000 |
Why?
| | Aneuploidy | 1 | 1988 | 90 | 0.000 |
Why?
| | Pituitary Gland | 1 | 1988 | 148 | 0.000 |
Why?
| | Fluorescent Antibody Technique | 1 | 1988 | 370 | 0.000 |
Why?
| | Cell Cycle | 1 | 1988 | 596 | 0.000 |
Why?
| | Flow Cytometry | 1 | 1988 | 1172 | 0.000 |
Why?
|
|
Breeze's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|